S Salas1,2, N Resseguier3, J Y Blay4, A Le Cesne5, A Italiano6, C Chevreau7, P Rosset8, N Isambert9, P Soulie10, D Cupissol11, C Delcambre12, J O Bay13, P Dubray-Longeras13, M Krengli14, B De Bari15, S Villa16, J H A M Kaanders17, S Torrente14, D Pasquier18, J O Thariat19, L Myroslav20, C V Sole21, H F Dincbas22, J Y Habboush23, T Zilli24, T Dragan25, K Khan R26, G Ugurluer27, T Cena28, F Duffaud1, N Penel29, F Bertucci30, D Ranchere-Vince31, P Terrier32, S Bonvalot33, N Macagno34, C Lemoine3, M Lae35, J M Coindre36,37, C Bouvier2,34. 1. Department of Medicine, Timone Hospital, Marseille. 2. Aix Marseille University, Marseille. 3. Support Unit for Clinical Research and Economic Evaluatin, Timone Hospital, Marseille. 4. Department of Medicine, Leon Berard Center, Lyon. 5. Department of Medicine, Gustave Roussy Institute, Villejuif. 6. Department of Medicine, Bergonié Institute, Bordeaux. 7. Department of Medicine, Claudius Regaud Institute, Toulouse. 8. Department of Medicine, CHU, Tours. 9. Department of Medicine, Georges-François Leclerc Institute, Dijon. 10. Department of Medicine, Paul Papin Institute, Angers. 11. Department of Medicine, Val d'Aurelle Institute, Montpellier. 12. Department of Medicine, François-Baclesse Institute, Caen. 13. Department of Medicine, Jean Perrin Institute, Clermont-Ferrand, France. 14. Department of Radiotherapy, University Hospital, Novara, Italy. 15. Department of Radiotherapy, CHU Vaudois, Lausanne, Switzerland. 16. Department of Radiotherapy, Catalan Institute of Oncology, Badalona Catalonia, Spain. 17. Department of Radiotherapy, Radboud University Medical Center, Nijmegen, The Netherlands. 18. Department of Radiotherapy, Centre Oscar Lambret, Lille. 19. Department of Radiotherapy, Centre Antoine-Lacassagne, Nice, France. 20. Department of Radiotherapy, Rambam HCC, Haifa, Israel. 21. Department of Radiotherapy, Clinica Instituto de Radiomedicina (IRAM), Santiago, Chile. 22. Department of Radiotherapy, Cerrahpasa Medical Faculty, Istanbul, Turkey. 23. Department of Radiotherapy, Mayo Clinic, Jacksonville, USA. 24. Department of Radiotherapy, HUG, Geneva, Switzerland. 25. Department of Radiotherapy, Institut J. Bordet Brussels, Brussels, Belgium. 26. Department of Radiotherapy, CHVR, Sion, Switzerland. 27. Department of Radiotherapy, Adana Hospital, Adana, Turkey. 28. Department of Medical Statistics, University of Piemonte Orientale, Novara, Italy. 29. Department of Medicine, Oscar Lambret Institute, Lille. 30. Department of Medicine, Paoli Calmette Institute, Marseille. 31. Department of Pathology, Leon Berard Center, Lyon. 32. Department of Pathology, Gustave Roussy Institute, Villejuif. 33. Department of Surgery, Institut Curie, PSL University, Paris. 34. Department of Pathology, Timone Hospital, Marseille. 35. Department of Pathology, Curie Institute, Paris. 36. Department of Pathology, Bergonié Institute, Bordeaux. 37. University Victor Ségalen, Bordeaux, France.
Abstract
BACKGROUND: Solitary fibrous tumors (SFT) are rare unusual ubiquitous soft tissue tumors that are presumed to be of fibroblastic differentiation. At present, the challenge is to establish accurate prognostic factors. PATIENTS AND METHODS: A total of 214 consecutive patients with SFT diagnosed in 24 participating cancer centers were entered into the European database (www.conticabase.org) to perform univariate and multivariate analysis for overall survival (OS), local recurrence incidence (LRI) and metastatic recurrence incidence (MRI) by taking competing risks into account. A prognostic model was constructed for LRI and MRI. Internal and external validations of the prognostic models were carried out. An individual risk calculator was carried out to quantify the risk of both local and metastatic recurrence. RESULTS: We restricted our analysis to 162 patients with local disease. Twenty patients (12.3%) were deceased at the time of analysis and the median OS was not reached. The LRI rates at 10 and 20 years were 19.2% and 38.6%, respectively. The MRI rates at 10 and 20 years were 31.4% and 49.8%, respectively. Multivariate analysis retained age and mitotic count tended to significance for predicting OS. The factors influencing LRI were viscera localization, radiotherapy and age. Mitotic count, tumor localization other than limb and age had independent values for MRI. Three prognostic groups for OS were defined based on the number of unfavorable prognostic factors and calculations were carried out to predict the risk of local and metastatic recurrence for individual patients. CONCLUSION: LRI and MRI rates increased between 10 and 20 years so relapses were delayed, suggesting that long-term monitoring is useful. This study also shows that different prognostic SFT sub-groups could benefit from different therapeutic strategies and that use of a survival calculator could become standard practice in SFTs to individualize treatment based on the clinical situation.
BACKGROUND: Solitary fibrous tumors (SFT) are rare unusual ubiquitous soft tissue tumors that are presumed to be of fibroblastic differentiation. At present, the challenge is to establish accurate prognostic factors. PATIENTS AND METHODS: A total of 214 consecutive patients with SFT diagnosed in 24 participating cancer centers were entered into the European database (www.conticabase.org) to perform univariate and multivariate analysis for overall survival (OS), local recurrence incidence (LRI) and metastatic recurrence incidence (MRI) by taking competing risks into account. A prognostic model was constructed for LRI and MRI. Internal and external validations of the prognostic models were carried out. An individual risk calculator was carried out to quantify the risk of both local and metastatic recurrence. RESULTS: We restricted our analysis to 162 patients with local disease. Twenty patients (12.3%) were deceased at the time of analysis and the median OS was not reached. The LRI rates at 10 and 20 years were 19.2% and 38.6%, respectively. The MRI rates at 10 and 20 years were 31.4% and 49.8%, respectively. Multivariate analysis retained age and mitotic count tended to significance for predicting OS. The factors influencing LRI were viscera localization, radiotherapy and age. Mitotic count, tumor localization other than limb and age had independent values for MRI. Three prognostic groups for OS were defined based on the number of unfavorable prognostic factors and calculations were carried out to predict the risk of local and metastatic recurrence for individual patients. CONCLUSION: LRI and MRI rates increased between 10 and 20 years so relapses were delayed, suggesting that long-term monitoring is useful. This study also shows that different prognostic SFT sub-groups could benefit from different therapeutic strategies and that use of a survival calculator could become standard practice in SFTs to individualize treatment based on the clinical situation.
Authors: Isidro Machado; Gema Nieto Morales; Julia Cruz; Javier Lavernia; Francisco Giner; Samuel Navarro; Antonio Ferrandez; Antonio Llombart-Bosch Journal: Virchows Arch Date: 2019-09-16 Impact factor: 4.064
Authors: Wei-Lien Wang; Nalan Gokgoz; Bana Samman; Irene L Andrulis; Jay S Wunder; Elizabeth G Demicco Journal: Mod Pathol Date: 2020-10-02 Impact factor: 7.842
Authors: Giuseppe Bianchi; Debora Lana; Marco Gambarotti; Cristina Ferrari; Marta Sbaraglia; Elena Pedrini; Laura Pazzaglia; Luca Sangiorgi; Isabella Bartolotti; Angelo Paolo Dei Tos; Katia Scotlandi; Alberto Righi Journal: Cancers (Basel) Date: 2021-05-19 Impact factor: 6.639